Rocket Lab Stock Gained 118% Over the Past Year. Is It Time to Buy?

Rocket Lab will buy Iridium Communications in an approximately $8B half-stock/half-cash deal to expand satellite communications, expected to close in 1H 2027. In Q1 2026, it also signed 31 additional launch contracts (record) and reported sales up nearly 64% to $200M, beating consensus (~$189M), with losses narrowing to $(0.07) per share vs consensus $(0.08). Despite strong growth, the article flags Neutron launch delay risk and ongoing unprofitability (Q1 loss: $45M) alongside an elevated 82x price-to-sales multiple versus a 9x sector average.

Analysis

The key market mechanism is not “space is hot”; it is that RKLB is trying to convert a highly valued, lumpy launch story into a hybrid recurring-revenue platform by paying with its own elevated equity. That is strategically smart if the multiple holds, but it also means any post-deal compression in RKLB’s valuation directly worsens the economics of the transaction and can make the acquisition look more dilutive than accretive. In other words, the equity currency is both the funding advantage and the embedded risk.

Near term, the stock is likely to trade on narrative momentum rather than pro forma earnings power, so the bigger swing factor is execution cadence: Neutron timing, integration credibility, and whether the company can show that launch wins are becoming a durable backlog rather than one-off enthusiasm. Over 1-3 months, any test-flight delay or financing detail that increases leverage or share issuance risk should hit RKLB faster than the market expects, because the current premium leaves little room for operational slippage.

The contrarian point is that the market may be overrating the “space platform” label and underweighting the fact that IRDM is a mature, cash-generative asset with different growth characteristics. That likely helps IRDM holders more than RKLB holders in the first leg of the trade, while also making defense and satellite incumbents more attractive on a risk-adjusted basis if buyers want space exposure without paying 80x+ sales. Falsify the bearish RKLB view if Neutron stays on schedule and management can lift forward revenue guidance without adding materially to dilution or debt.

Key Decisions for Investors

• Avoid chasing RKLB into strength; wait for post-news pullbacks or a confirmed Neutron test-flight date before adding risk. The stock is priced for near-perfect execution, so any delay is the cleaner short-term catalyst than the upside case.
• Conditional relative-value: long IRDM / short RKLB if the market leaves a wide gap between IRDM’s standalone value and the implied deal economics. This is the cleaner way to express skepticism on RKLB’s use of expensive equity as acquisition currency.
• If you want upside exposure, use RKLB call spreads rather than outright stock into the Neutron catalyst window. That keeps participation in a successful launch while limiting damage if the timeline slips or the deal terms pressure the multiple.
• Set an alert around any guidance update that implies heavier-than-expected dilution or balance-sheet stretch. That would be the first hard sign that the acquisition is value-destructive rather than strategic.
• Watch defense-space primes and satellite incumbents for secondary benefit if RKLB’s deal distracts management: they can win on procurement continuity while RKLB integrates. If contract awards shift away from RKLB, treat that as a medium-term warning signal.